Alnylam reviews pre-clinical data from ALN-AS1 program for treatment of AIP Alnylam Pharmaceuticals.

The brand new research outcomes support the advancement of RNAi therapeutics as a promising technique for the avoidance and/or treatment of severe attacks in individuals with AIP. In the brand new studies, Alnylam researchers and collaborators at Icahn College of Medication at Mount Sinai shown results from a mouse model of AIP. Prophylactic administration of an ALAS-1 particular siRNA completely covered the mice from phenobarbital-induced up-regulation of hepatic ALAS-1 mRNA and the resulting accumulation of the neurotoxic ALA and PBG heme biosynthesis precursors.Serves: 10 Meal: ¾ cup Nutritional analysis : 365 calories 15 g protein 24 g fat 311 mg calcium 896 mg sodium Note: Nutritional analysis can vary greatly based on ingredient brands used.. Childhood absence epilepsy: Comparative clinical trial of trusted anti-seizure drugs The first comprehensive comparative effectiveness clinical trial of three trusted anti-seizure medicines for childhood absence epilepsy – the most common form of epilepsy in kids – has generated an evidence-based approach for initial medication therapy. Released March 4 in the New England Journal of Medicine, data from the double-blind, randomized, comparative clinical trial fill a big details gap in the treating childhood absence epilepsy, also called petit mal epilepsy.